143 related articles for article (PubMed ID: 2872186)
1. Inhibition of cytotoxicity by sulfasalazine. I. Sulfasalazine inhibits spontaneous cell-mediated cytotoxicity by peripheral blood and intestinal mononuclear cells from control and inflammatory bowel disease patients.
MacDermott RP; Kane MG; Steele LL; Stenson WF
Immunopharmacology; 1986 Apr; 11(2):101-9. PubMed ID: 2872186
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of antibody secretion by 5-aminosalicylic acid.
MacDermott RP; Schloemann SR; Bertovich MJ; Nash GS; Peters M; Stenson WF
Gastroenterology; 1989 Feb; 96(2 Pt 1):442-8. PubMed ID: 2562949
[TBL] [Abstract][Full Text] [Related]
3. Sulphasalazine and derivatives, natural killer activity and ulcerative colitis.
Gibson PR; Jewell DP
Clin Sci (Lond); 1985 Aug; 69(2):177-84. PubMed ID: 2866061
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes.
Shanahan F; Niederlehner A; MacDermott RP; Stenson WF; Kane MG; Targan S
Immunopharmacology; 1986 Apr; 11(2):111-8. PubMed ID: 2872187
[TBL] [Abstract][Full Text] [Related]
5. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products.
Tornhamre S; Edenius C; Smedegård G; Sjöquist B; Lindgren JA
Eur J Pharmacol; 1989 Oct; 169(2-3):225-34. PubMed ID: 2572437
[TBL] [Abstract][Full Text] [Related]
6. Increased suppressor cell activity in inflammatory bowel disease.
Holdstock G; Chastenay BF; Krawitt EL
Gut; 1981 Dec; 22(12):1025-30. PubMed ID: 6119275
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of cytotoxic effector cells and antibody producing cells from human intestine.
MacDermott RP
Acta Chir Scand Suppl; 1985; 525():25-43. PubMed ID: 3875204
[TBL] [Abstract][Full Text] [Related]
8. The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis.
Molin L; Stendahl O
Acta Med Scand; 1979; 206(6):451-7. PubMed ID: 43662
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
Klotz U; Maier K; Fischer C; Heinkel K
N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-alpha production by mast cells.
Bissonnette EY; Enciso JA; Befus AD
J Immunol; 1996 Jan; 156(1):218-23. PubMed ID: 8598465
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of leucocyte motility by drugs used in ulcerative colitis.
Rhodes JM; Bartholomew TC; Jewell DP
Gut; 1981 Aug; 22(8):642-7. PubMed ID: 6116649
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: differences between ulcerative colitis, Crohn's disease, and controls.
Scott MG; Nahm MH; Macke K; Nash GS; Bertovich MJ; MacDermott RP
Clin Exp Immunol; 1986 Oct; 66(1):209-15. PubMed ID: 3802572
[TBL] [Abstract][Full Text] [Related]
13. Deficient cell-mediated cytotoxicity and hyporesponsiveness to interferon and mitogenic lectin activation by inflammatory bowel disease peripheral blood and intestinal mononuclear cells.
MacDermott RP; Bragdon MJ; Kodner IJ; Bertovich MJ
Gastroenterology; 1986 Jan; 90(1):6-11. PubMed ID: 3940256
[TBL] [Abstract][Full Text] [Related]
14. Drug therapy of inflammatory bowel disease.
Sack DM; Peppercorn MA
Pharmacotherapy; 1983; 3(3):158-76. PubMed ID: 6136027
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine.
Das KM
Postgrad Med; 1983 Dec; 74(6):141-8, 150-1. PubMed ID: 6139795
[TBL] [Abstract][Full Text] [Related]
16. Desensitization of patients with inflammatory bowel disease to sulfasalazine.
Taffet SL; Das KM
Am J Med; 1982 Oct; 73(4):520-4. PubMed ID: 6127032
[TBL] [Abstract][Full Text] [Related]
17. Intestinal immune reactivity to interleukin 2 differs among Crohn's disease, ulcerative colitis, and controls.
Kusugami K; Youngman KR; West GA; Fiocchi C
Gastroenterology; 1989 Jul; 97(1):1-9. PubMed ID: 2785943
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.
Aparicio-Pagés MN; Verspaget HW; Hafkenscheid JC; Crama-Bohbouth GE; Peña AS; Weterman IT; Lamers HW
Gut; 1990 Sep; 31(9):1030-2. PubMed ID: 1976576
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of MIP-3alpha/CCL20 in peripheral blood mononuclear cells from patients with ulcerative colitis and its down-regulation by sulfasalazine and glucocorticoid treatment.
Lee HJ; Choi SC; Lee MH; Oh HM; Choi EY; Choi EJ; Yun KJ; Seo GS; Kim SW; Lee JG; Han WC; Park KI; Jun CD
Inflamm Bowel Dis; 2005 Dec; 11(12):1070-9. PubMed ID: 16306769
[TBL] [Abstract][Full Text] [Related]
20. [Mode of action of sulfasalazine in chronic inflammatory enterocolonic diseases].
Delboy H
Therapie; 1992; 47(2):157-9. PubMed ID: 1357770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
